Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Stock Information for Tenax Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tenax Therapeutics Inc.

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Tenax Therapeutics to Host KOL Event: "LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study"

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.